Unlike Colon 26 tumors, resiquimod monotherapy in SCCVII tumors with impaired CD8+ T cell activation and accelerated Treg recruitment in the TME markedly decreased tumor size along with CD8+ T cell accumulation and a reduction of Tregs. Here, CD8A is linked to neoplasm.